July 3, 2012, London, United Kingdom, and Shenzhen, China The symposium themed "The Era of Next Generation Sequencing in Cancer", co-organized by BGI, the world's largest genomics organization, and Imperial College London, was successfully conducted in London, UK. Around 70 experts, scholars, and representatives from the local colleges, institutes and biotechnology industries attended the meeting with the aim to exchange their insights on high-throughput genomics and accelerate the further development of cancer research.
The symposium started with a friendly opening remark by Professor Charles Coombes, Director of Division of Cancer, Imperial College, and Hon Consultant Medical Oncologist, Imperial College Healthcare Trust. He was delighted to be the chairman of the symposium, and said:" The symposium is a good start between Imperial College London and BGI. We are looking forward to more collaboration with BGI, one of the largest genomics organizations in the world. We are confident that we will make more breakthroughs together in the near future."
After that, experts delivered several excellent presentations highlighting the advancements in cancer research, including "Cancer genome research in BGI", "Understanding estrogen receptor transcription in breast cancer", "Genetic analysis of five cancers using single-cell sequencing", "Genetic regulation of the rat cardiac methylome", "Personalized epigenetic therapy in follicular lymphoma", "Biomarker discovery through integrated next-generation sequencing (NGS) genomic analysis of neuroendocrine tumors", among others.
Yingrui Li, Vice Director of BGI, shared several case studies on cancer genome research applying BGI's NGS and bioinformatics technologies. He referred that the object of their studies is to make more contributions in cancer research and boost the transformation of scientific discoveries to benefit human health. He emphasized that, "NGS technologies, especially single-cell se
|Contact: Jia Liu|